Beta-blockers and fetal growth restriction in pregnant women with cardiovascular disease

Kayo Tanaka, Hiroaki Tanaka, Chizuko Kamiya, Shinji Katsuragi, Masami Sawada, Mitsuhiro Tsuritani, Masashi Yoshida, Naoko Iwanaga, Jun Yoshimatsu, Tomoaki Ikeda

Research output: Contribution to journalArticlepeer-review

52 Citations (Scopus)


Background: The effects of β-adrenergic blockers on the fetus are not well understood. We analyzed the maternal and neonatal outcomes of β-adrenergic blocker treatment during pregnancy to identify the risk of fetal growth restriction (FGR). Methods and Results: We retrospectively reviewed 158 pregnancies in women with cardiovascular disease at a single center. Maternal and neonatal outcomes were analyzed in 3 categories: the carvedilol (α/β-adrenergic blocker; α/β group, n=13); β-adrenergic blocker (β group, n=45), and control groups (n=100). Maternal outcome was not significantly different between the groups. FGR occurred in 1 patient (7%) in the α/β group, in 12 (26%) in the β group, and in 3 (3%) in the control group; there was a significant difference between the incidence of FGR between the β group and control group (P<0.05). The β group included propranolol (n=22), metoprolol (n=12), atenolol (n=6), and bisoprolol (n=5), and the individual incidence of FGR with these medications was 36%, 17%, 33%, and 0%, respectively. Conclusions: As a group, β-adrenergic blockers were significantly associated with FGR, although the incidence of FGR varied with individual β-blocker. Carvedilol, an α/β-adrenergic blocker, had no association with FGR. More controlled studies are needed to fully establish such associations.

Original languageEnglish
Pages (from-to)2221-2226
Number of pages6
JournalCirculation Journal
Issue number10
Publication statusPublished - 2016
Externally publishedYes


  • Beta-adrenergic blocker
  • Cardiovascular disease
  • Fetal growth restriction
  • Pregnancy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Beta-blockers and fetal growth restriction in pregnant women with cardiovascular disease'. Together they form a unique fingerprint.

Cite this